Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
27.12M | 15.84M | 106.48M | 524.00M | 37.51M | Gross Profit |
25.85M | 2.21M | 103.14M | 499.03M | -84.89M | EBIT |
-184.29M | -282.87M | -143.16M | 310.62M | -125.43M | EBITDA |
-160.75M | -253.10M | -108.02M | 319.00M | -126.97M | Net Income Common Stockholders |
-239.56M | -308.48M | -126.79M | 329.59M | -125.02M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
367.52M | 617.89M | 352.84M | 556.26M | 244.93M | Total Assets |
556.54M | 831.69M | 704.96M | 809.18M | 340.39M | Total Debt |
66.06M | 138.41M | 142.89M | 135.72M | 71.54M | Net Debt |
-92.87M | -102.95M | -85.12M | -420.53M | -173.39M | Total Liabilities |
563.29M | 624.02M | 228.96M | 213.40M | 96.49M | Stockholders Equity |
-6.75M | 207.67M | 476.01M | 595.78M | 243.91M |
Cash Flow | Free Cash Flow | |||
-186.10M | -153.08M | -162.75M | 270.52M | -144.31M | Operating Cash Flow |
-182.73M | -145.93M | -145.06M | 287.96M | -134.83M | Investing Cash Flow |
162.97M | -205.69M | -182.73M | -67.39M | -9.48M | Financing Cash Flow |
-59.49M | 362.72M | 1.45M | 94.86M | 7.44M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $13.46B | 32.10 | 8.05% | ― | 17.35% | 151.40% | |
69 Neutral | $9.77B | 41.86 | 19.71% | ― | 52.97% | ― | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
46 Neutral | $3.63B | ― | -19.20% | ― | -89.95% | -123.71% | |
45 Neutral | $675.96M | ― | -238.46% | ― | 71.17% | 23.89% | |
42 Neutral | $38.57M | ― | -270.20% | ― | 144.50% | -141.91% | |
42 Neutral | $100.68M | ― | -76.26% | ― | -72.22% | 51.95% |
uniQure has reached an agreement with the FDA on critical elements for the Accelerated Approval pathway for AMT-130, a promising gene therapy for Huntington’s disease. The FDA’s acceptance of data from Phase I/II studies, along with the use of cUHDRS as a clinical endpoint, marks a significant milestone towards delivering this potential treatment. The company plans to engage further with the FDA in 2025, aiming to expedite the availability of AMT-130, which has shown promising results in slowing disease progression.